

# Penelope Ward

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6025378/publications.pdf>

Version: 2024-02-01

24  
papers

5,110  
citations

331670

21  
h-index

610901

24  
g-index

25  
all docs

25  
docs citations

25  
times ranked

3208  
citing authors

#	ARTICLE	IF	CITATIONS
1	18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. <i>Practical Radiation Oncology</i> , 2020, 10, 354-362.	2.1	9
2	The Impact of Positron Emission Tomography with <sup>18</sup> F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. <i>Journal of Urology</i> , 2019, 201, 322-331.	0.4	113
3	Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using <sup>18</sup> F-Fluciclovine PET/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1596-1602.	5.0	33
4	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ( <sup>18</sup> F) PET/CT in Biochemically Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 676-683.	0.4	165
5	Antivirals for influenza in healthy adults. <i>Lancet, The</i> , 2006, 367, 1571.	13.7	16
6	The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2556-2562.	0.7	63
7	Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, i5-i21.	3.0	357
8	Management of Influenza in Households: A Prospective, Randomized Comparison of Oseltamivir Treatment With or Without Postexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2004, 189, 440-449.	4.0	301
9	Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1;1/2-7 years. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 411-415.	1.9	66
10	A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 977-990.	3.0	102
11	Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations. <i>Archives of Internal Medicine</i> , 2003, 163, 1667.	3.8	443
12	Viral Respiratory Infection in Schoolchildren: Effects on Middle Ear Pressure. <i>Pediatrics</i> , 2002, 109, 826-832.	2.1	60
13	Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1993-1995.	3.2	22
14	Oral oseltamivir treatment of influenza in children. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 127-133.	2.0	684
15	Long-Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 1025-1031.	2.6	168
16	The Pharmacokinetics and Tolerability of the Oral Neuraminidase Inhibitor Oseltamivir (Ro) in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 836-843.	2.0	71
17	Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 1016.	7.4	909
18	Oral Oseltamivir in Human Experimental Influenza B Infection. <i>Antiviral Therapy</i> , 2000, 5, 205-213.	1.0	81

#	ARTICLE	IF	CITATIONS
19	Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza. JAMA - Journal of the American Medical Association, 1999, 282, 1240.	7.4	500
20	Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. New England Journal of Medicine, 1999, 341, 1336-1343.	27.0	477
21	Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802. Clinical Pharmacokinetics, 1999, 37, 471-484.	3.5	361
22	Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. Aids, 1996, 10, 1357-1360.	2.2	12
23	Effect of age and gender on tirilazad pharmacokinetics in humans. Clinical Pharmacology and Therapeutics, 1994, 55, 378-384.	4.7	75
24	Smoking and DNA damage in cervical cells. Lancet, The, 1990, 335, 417.	13.7	22